Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study

The safety of obinutuzumab, alone or with chemotherapy, was studied in a non-randomized, open-label, non-comparative, phase IIIb study (GREEN) in previously untreated or relapsed/refractory chronic lymphocytic leukemia. Patients received obinutuzumab 1000 mg alone or with chemotherapy (investigator’...

Descripción completa

Detalles Bibliográficos
Autores principales: Leblond, Véronique, Aktan, Melih, Ferra Coll, Christelle M., Dartigeas, Caroline, Kisro, Jens, Montillo, Marco, Raposo, João, Merot, Jean-Louis, Robson, Susan, Gresko, Ekaterina, Bosch, Francesc, Stilgenbauer, Stephan, Foà, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278964/
https://www.ncbi.nlm.nih.gov/pubmed/29976743
http://dx.doi.org/10.3324/haematol.2017.186387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278964/
https://www.ncbi.nlm.nih.gov/pubmed/29976743
http://dx.doi.org/10.3324/haematol.2017.186387

Ejemplares similares